Get the Stockscreener App
23.31
2.78%
0.6411
Innoviva Inc stock is traded at $23.31, with a volume of 255.69K.
It is up +2.78% in the last 24 hours and up +3.74% over the past month.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
See More
Previous Close:
$22.67
Open:
$22.81
24h Volume:
255.69K
Relative Volume:
0.33
Market Cap:
$1.72B
Revenue:
$434.49M
Net Income/Loss:
$504.34M
P/E Ratio:
3.8763
EPS:
6.0138
Net Cash Flow:
$181.97M
1W Performance:
+3.06%
1M Performance:
+3.74%
6M Performance:
+19.43%
1Y Performance:
+11.92%
1-Day Range:
$22.68
$23.37
1-Week Range:
$22.22
$23.37
52-Week Range:
$16.52
$25.14
Innoviva Inc Stock (INVA) Company Profile
Name
Innoviva Inc
Sector
Industry
Phone
(650) 238-9600
Address
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
23.31 | 1.66B | 434.49M | 504.34M | 181.97M | 6.0138 |
VRTX
Vertex Pharmaceuticals Inc
|
469.56 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
618.27 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.81 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.43 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
167.68 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | BTIG Research | Buy |
| Sep-30-25 | Initiated | Goldman | Sell |
| Aug-11-25 | Initiated | Oppenheimer | Outperform |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-20-22 | Initiated | Goldman | Neutral |
| Nov-20-17 | Initiated | Deutsche Bank | Hold |
View All
Innoviva Inc Stock (INVA) Latest News
Innoviva Inc (INVA) Institutional Confidence - TradingKey
H.C. Wainwright Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Innoviva Is Maintained at Buy by BTIG - Moomoo
H.C. Wainwright reiterates Innoviva stock rating on drug delivery platform - Investing.com
H.C. Wainwright reiterates Innoviva stock rating on drug delivery platform By Investing.com - Investing.com Nigeria
Innoviva stock trades down to $22.49 as Western Thoracic conference focus draws attention - Traders Union
Innoviva stock trades down to $22.49 as company highlights role of ATC2026 in transplant research - Traders Union
Will XACDURO Licensing Deal With Dr. Reddy’s Reshape Innoviva’s (INVA) Infectious Disease Strategy? - simplywall.st
Innoviva’s Nortiva Bio launches to develop long-acting oral medicines - TipRanks
Nortiva Bio Launches to Develop Long-Acting Oral Medicines - Business Wire
Innoviva Inc (NASDAQ:INVA): A GARP Standout with 470% EPS Growth and a P/E of Just 6.05 - ChartMill
Innoviva Inc (INVA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Innoviva, Inc. acquired LYNX platform from Lyndra Therapeutics, Inc. - marketscreener.com
Innoviva Inc (INVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Innoviva Inc (INVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Innoviva Inc (INVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Innoviva Inc (INVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Innoviva Inc (INVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Innoviva Inc (INVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Innoviva Inc (INVA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Innoviva Specialty Therapeutics inks distribution and licensing agreement with Dr. Reddy’s - BioSpectrum India
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO - Business Wire
Innoviva partners with Dr. Reddy's for XACDURO licensing - grafa.com
Innoviva unit signs distribution deal with Dr. Reddy’s By Investing.com - Investing.com Nigeria
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets - BioSpace
Innoviva unit signs distribution deal with Dr. Reddy’s - Investing.com
Responsive Playbooks and the INVA Inflection - Stock Traders Daily
INVA Q1 2026 Earnings: EPS Falls Far Short of Estimates, Stock DeclinesRevenue Per Share - newsline.com
Innoviva Inc. (INVA) Q1 2026 Earnings: Significant EPS Miss Despite Positive Stock ReactionQuarterly Earnings Report - newsline.com
Innoviva stock rises to $23.00 amid constructive trends and renewed buyer momentum - Traders Union
INVA Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; Stock Rises 0.94%Final Results - newsline.com
Innoviva (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary - Quartr
Understanding the Setup: (INVA) and Scalable Risk - Stock Traders Daily
Innoviva Board Shift And New Treatment Launch Create Valuation Question - Sahm
Innoviva, Inc. to Present at Investor Conferences - geneonline.com
Innoviva to Participate in Upcoming Investor Conferences - New Castle News
INVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $46 - GuruFocus
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More - AOL.com
Has Innoviva Successfully Pivoted Beyond its Royalty Roots - Kavout
INVA Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclineFull Year Guidance - The Legal Advocate
INVA Q1 2026 Earnings: EPS Miss Triggers 2% Stock DeclineDividend Cut Risk - The Legal Advocate
Innoviva (INVA) Holds Near Key Support on Light Volume as Biotech Sector Navigates UncertaintyBullish Pattern Stocks - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI), NeOnc Technologies Holdings, Inc. (NTHI) and Innoviva (INVA) - The Globe and Mail
Innoviva (INVA) Q1 2026 Earnings: EPS Misses Estimates by Over 112%, Stock DeclinesEarnings Call Highlights - newsline.com
INVA Reiterates by BTIG -- Price Target Maintained at $42 - GuruFocus
Innoviva Inc. (INVA) Gains Ground Amid Sector DynamicsPost-Earnings Moves - The Legal Advocate
INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals - ChartMill
The Technical Signals Behind (INVA) That Institutions Follow - Stock Traders Daily
INVA Q1 2026 Earnings: Significant EPS Miss Amid Lack of Revenue DisclosureOne-Time Loss Impact - Newser
INVA Q1 2026 Earnings: EPS Misses Estimates Despite Modest Stock GainOpen Signal Network - Newser
Innoviva (INVA) CFO adds ESPP shares and uses stock to pay taxes - Stock Titan
Innoviva Inc Stock (INVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):